LeMaitre Vascular Inc (NASDAQ:LMAT) – Investment analysts at First Analysis issued their Q4 2018 earnings estimates for LeMaitre Vascular in a research report issued to clients and investors on Friday. First Analysis analyst expects that the medical instruments supplier will earn $0.28 per share for the quarter. First Analysis also issued estimates for LeMaitre Vascular’s FY2019 earnings at $1.13 EPS.
A number of other analysts have also weighed in on LMAT. BidaskClub lowered LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Saturday, December 2nd. Zacks Investment Research upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a report on Thursday, December 28th. Finally, Canaccord Genuity restated a “hold” rating and set a $33.00 target price on shares of LeMaitre Vascular in a report on Friday, February 23rd. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $34.00.
LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Wednesday, February 21st. The medical instruments supplier reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.20 by $0.01. The company had revenue of $26.15 million during the quarter, compared to analyst estimates of $26.23 million. LeMaitre Vascular had a return on equity of 16.93% and a net margin of 17.03%. LeMaitre Vascular’s revenue was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.13 earnings per share.
The business also recently announced a quarterly dividend, which will be paid on Thursday, April 5th. Shareholders of record on Thursday, March 22nd will be issued a dividend of $0.07 per share. The ex-dividend date is Wednesday, March 21st. This represents a $0.28 dividend on an annualized basis and a yield of 0.76%. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.06. LeMaitre Vascular’s dividend payout ratio is currently 25.88%.
In other news, Chairman George W. Lemaitre sold 30,000 shares of the company’s stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $36.19, for a total transaction of $1,085,700.00. Following the transaction, the chairman now directly owns 3,180,709 shares of the company’s stock, valued at $115,109,858.71. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Chairman George W. Lemaitre sold 45,000 shares of the company’s stock in a transaction on Monday, March 5th. The stock was sold at an average price of $34.66, for a total value of $1,559,700.00. Following the transaction, the chairman now directly owns 3,225,709 shares in the company, valued at $111,803,073.94. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 137,736 shares of company stock valued at $4,866,186. 23.70% of the stock is owned by company insiders.
Several hedge funds have recently modified their holdings of LMAT. Northern Trust Corp increased its position in shares of LeMaitre Vascular by 9.8% during the second quarter. Northern Trust Corp now owns 239,671 shares of the medical instruments supplier’s stock worth $7,483,000 after purchasing an additional 21,473 shares in the last quarter. Vanguard Group Inc. increased its position in shares of LeMaitre Vascular by 23.5% during the second quarter. Vanguard Group Inc. now owns 815,580 shares of the medical instruments supplier’s stock worth $25,462,000 after purchasing an additional 155,249 shares in the last quarter. Voya Investment Management LLC acquired a new position in shares of LeMaitre Vascular during the second quarter worth $203,000. Royal Bank of Canada increased its position in shares of LeMaitre Vascular by 856.5% during the second quarter. Royal Bank of Canada now owns 5,031 shares of the medical instruments supplier’s stock worth $157,000 after purchasing an additional 4,505 shares in the last quarter. Finally, State Street Corp increased its position in shares of LeMaitre Vascular by 25.2% during the second quarter. State Street Corp now owns 382,824 shares of the medical instruments supplier’s stock worth $11,951,000 after purchasing an additional 77,009 shares in the last quarter. 72.88% of the stock is currently owned by institutional investors and hedge funds.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.